Themis

Themis is the company specializing in vaccines and immunomodulatory methods of treatment of infectious diseases and cancer. Themis locates the wide range of the candidate vaccines and potential immunomodulatory medicines developed using the innovation platform on the basis of virus vectors.

History

2020: Merck of a kupli Themis

In the middle of June, 2020 Merck purchased the developer of the vaccines Themis. The cost and other terms of transaction of the company did not begin to open.

Due to the pandemic Federal trade commission of the USA allowed the company to close ahead of schedule a latent period which is supposed to be sustained according to the Law on gain of the antitrust law of Hart-Scott-Rodino of 1976. Besides, Merck got permission to a company merger from Federal management of Austria on the competition thanks to what Themis company completely is owned now by Merck.

Merck purchased the developer of vaccine against COVID-19

It is known that both companies cooperate in the development area of vaccinal candidates and potential medicines long ago. Now, when Themis became full-fledged branch Merck, the companies intend to develop vaccine against SARS-CoV-2 on the basis of a virus vector of measles in an expedited manner.

According to the press release, the candidate for creation of vaccine is in development at a preclinical stage, and is going to begin clinical trials at the end of 2020. Earlier Merck announced that it also cooperates with IAVI for development of research vaccine against SARS-CoV-2. Merck also reported that it intends to use the Vaxxas platform ‘High-Density Microarray Patch (HD-MAP) as the platform for candidate vaccine introduction.^[1]

In March, 2020 Themis joined consortium for development of candidate vaccine against COVID-19 and received investments from the Coalition for innovations in the field of readiness for epidemics (CEPI).

Notes